Johnson & Johnson submits application to the European Medicines Agency seeking approval of a new indication for IMBRUVICA® (ibrutinib) in adult patients with previously untreated mantle cell lymphoma (MCL) who are eligible for autologous stem cell transplant
Portfolio Pulse from
Johnson & Johnson has applied to the European Medicines Agency for approval of a new indication for IMBRUVICA® (ibrutinib) in treating adult patients with previously untreated mantle cell lymphoma (MCL) eligible for autologous stem cell transplant. This follows the Phase 3 TRIANGLE study results.
December 18, 2024 | 9:15 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Johnson & Johnson has submitted an application to the European Medicines Agency for a new indication of IMBRUVICA® in treating mantle cell lymphoma, based on positive Phase 3 study results.
The application for a new indication of IMBRUVICA® could expand its market and increase sales if approved, positively impacting JNJ's stock. The Phase 3 study results support the efficacy of the treatment, increasing the likelihood of approval.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 90